Merck Sharp & Dohme LLC has patented new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

TR-FRET（Time-Resolved Fluorescence Resonance Energy Transfer，时间分辨荧光共振能量转移）是一种用于研究分子间相互作用的生物物理技术。它结合了两种技术：荧光共振能量转移(FRET)和时间分辨荧光（TRF，Time-Resolved Fluorescence）。 荧光共振能量转移是一种物理现象，其中 ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

That is ASP3082, a novel protein degrader that targets mutated KRAS G12D and follows in the footsteps of Amgen’s KRAS inhibitor Lumakras (sotorasib), which became the first drug in the class to ...

A randomized, phase 2 clinical trial shows that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer ...

Objective We aim to unveil the consequences of mutant Gnas R201C expression on phenotype, transcriptomic profile and genomic dependencies. Data are available in a public, open access repository. Bulk ...

Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the "Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR) ...